Chemomab Therapeutics Ltd
NASDAQ:CMMB
Chemomab Therapeutics Ltd
NASDAQ:CMMB
Price:
0.8311 USD
-3.36%
Updated:
May 21, 2024
Chemomab Therapeutics Ltd
Income from Continuing Operations
|
Chemomab Therapeutics Ltd
Income from Continuing Operations Peer Comparison
Comparables:
CLGN
KMDA
URGN
ENTX
B
BONS
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Chemomab Therapeutics Ltd
NASDAQ:CMMB
|
Income from Continuing Operations
-$24.2m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Income from Continuing Operations
-$7m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Income from Continuing Operations
$12.5m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Income from Continuing Operations
-$104.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Income from Continuing Operations
-$8.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Income from Continuing Operations
-₪28.5m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-11%
|
See Also
What is Chemomab Therapeutics Ltd's Income from Continuing Operations?
Income from Continuing Operations
-24.2m
USD
-24.2m
USD
Based on the financial report for Dec 31, 2023, Chemomab Therapeutics Ltd's Income from Continuing Operations amounts to -24.2m USD.
What is Chemomab Therapeutics Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-28%
-28%
Over the last year, the Income from Continuing Operations growth was 12%. The average annual Income from Continuing Operations growth rates for Chemomab Therapeutics Ltd have been -28% over the past three years .
You don't have any saved screeners yet
